London, UK – October 18, 2022
GSK has entered into a $70 million agreement with Tempus, a leader in AI-driven precision medicine, to enhance its access to de-identified patient data and AI-powered tools. This collaboration is designed to improve clinical trial design, speed up patient enrollment, and identify novel drug targets, reinforcing GSK’s commitment to next-generation, AI-driven drug discovery.
Advancing Precision Medicine with AI
Under the partnership, GSK will gain access to Tempus’ expansive dataset—sourced from a network of over 40% of U.S. oncologists operating in academic and community healthcare settings. Tempus’ platform, among the largest oncology data networks globally, uses machine learning to match patients to the most appropriate clinical trials and treatments.
“This partnership enables us to leverage cutting-edge AI and machine learning to drive innovation in drug development,” said Tony Wood, Chief Scientific Officer at GSK.
“By integrating Tempus’ data capabilities with our AI-driven R&D, we can improve trial efficiency and bring personalized treatments to patients faster.”
Strengthening AI Leadership in Biopharma
This deal builds on a 2020 GSK–Tempus partnership focused on AI-enhanced patient matching for clinical trial enrollment. Since then, GSK has dramatically expanded its AI initiatives, with over 70% of its current drug pipeline now supported by genetically validated targets.
“We recognized early on the potential of AI in biopharma,” a GSK spokesperson said.
“With the industry’s largest in-house AI/ML team of 165 experts, we are continuously advancing data-driven drug discovery and development.”
Long-Term AI-Driven Innovation
The initial agreement spans three years, with an option to extend for an additional two years. As part of the collaboration, GSK and Tempus are also working together on a Phase II study of Zejula, GSK’s oncology drug candidate.
Beyond Tempus, GSK has formed strategic partnerships with PathAI for oncology and NASH (non-alcoholic steatohepatitis) research. It is also investing in global AI infrastructure through its London-based AI research hub, in collaboration with Cerebras, the Francis Crick Institute, and the Alan Turing Institute.
About Tempus
Tempus is a leader in AI and precision medicine, applying machine learning and real-world patient data to advance treatment in oncology and beyond. The company collaborates with major biopharmaceutical firms including AstraZeneca and Eli Lilly, and is backed by investors such as Google and Novo Holdings.
Read more on GSK’s official announcement
By